Zydus Cadila seeks emergency use approval from DCGI for its DNA vaccine for those aged 12 years and above

Pharmaceutical major Zydus Cadila has applied for Emergency Use Authorisation (EUA) seeking approval from the Drugs Controller General of India (DCGI) for the launch of their ZyCoV-D vaccine for 12 years and above.

According to the sources, the vaccine has completed the third phase trial.  is a DNA COVID vaccine, which carries the genetic code for that part of a virus that triggers the immune system of the body.

It will be the world’s first DNA vaccine against COVID and the second indigenous vaccine to apply for such authorisation.

“Zydus Cadila has told the government that it could apply for emergency use authorisation for ZyCoV-D vaccine in the next seven-eight days,” a government source had earlier said.

‘ZyCoV-D shots to be available soon’ 

Earlier on Sunday, the Central government had informed the Supreme Court that Zydus Cadila has concluded its clinical trial of DNA vaccine for children between the age group of 12 to 18 years and the shots will be available soon.

“It is submitted that Zydus Cadila which is developing DNA vaccines has concluded its clinical trial for between the age group of 12 to 18 years of age and subject to the statutory permissions, the same may be available in near future for children in the age group of 12 to 18 years of age,” the Centre had said in its affidavit filed in the top court in the suo motu matter on COVID management.


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies